Zentalis to present clinical data from Phase 1b trial of azenosertib

Zentalis Pharmaceuticals announced today that it will present positive clinical data from its Phase 1b trial investigating azenosertib in combination with chemotherapy in patients with advanced platinum-resistant ovarian cancer in a poster at the American Society of Clinical Oncology Meeting in Chicago, June 2-6, 2023. Azenosertib is the Company’s potentially first-in-class Wee1 inhibitor currently being investigated in multiple clinical trials as a monotherapy and in combination. The poster, entitled "Correlation of Cyclin E1 expression and clinical outcomes in a Phase 1b dose- escalation study of Azenosertib, a Wee1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or refractory epithelial ovarian, peritoneal, or fallopian tube cancer," will be presented on June 5, 2023, from 1:15 PM-4:15 PM CT and the poster discussion session will be on June 5, 2023, from 4:30 PM-6:00 PM CT. "We are pleased to have the opportunity to share these exciting clinical data from our chemotherapy combination trial at ASCO this year. These encouraging clinical data, together with the preclinical data we recently presented at the 2023 AACR Annual Meeting, provide clear support for the use of Cyclin E1 expression as a predictive marker to identify patients who may significantly benefit from treatment with azenosertib," said Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis. "Importantly, these findings offer robust evidence that azenosertib restores chemotherapy sensitivity in Cyclin E1 positive cancers, which are known to be chemotherapy resistant.